News Sentiment

SYRE sentiment intelligence

Spyre Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 60 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 97.74 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 52

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend active

+12.8% over one week, +21.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Spyre Therapeutics stock hits 52-week high at 102.46 USD

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction 12.8% Price confirming higher
Trend fit Trend active 21.0% over four weeks
Fair value 237.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 39
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 52
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
Market source 10
TradingView 6
Investing.com 4
MT Newswires 3
Quiver Quantitative 2
Moomoo 2
Quartr 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 16
Analyst action 4
Deals and strategy 3
Guidance 2
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 60
Investing.com Direct company coverage

Spyre Therapeutics stock hits 52-week high at 102.46 USD

Spyre Therapeutics (SYRE) stock reached a new 52-week high of $102.46, marking a significant surge from its 52-week low. This performance is attributed to positive phase 2 trial results for SPY002 targeting ulcerative colitis and completed enrollment for SPY072 in rheumatic disea

Tone
Positive 82/100
Event
Earnings
Published
14 Jul 2026 23:44
Source
Investing.com
Investing.com South Africa Direct company coverage

Spyre Therapeutics stock hits 52-week high at 102.46 USD By Investing.com

Spyre Therapeutics stock reached a new 52-week high of $102.46, reflecting a 550.33% increase over the past year. This surge follows positive Phase 2 trial results for its drug SPY002 and the completion of enrollment for its SKYWAY basket trial. Analyst firms Mizuho and Deutsche

Tone
Positive 86/100
Event
Earnings
Published
14 Jul 2026 15:39
Source
Investing.com South Africa
Investing.com Australia Direct company coverage

Mizuho raises Spyre stock price target to $120 on IBD data

Mizuho has increased its price target for Spyre Therapeutics (NASDAQ:SYRE) shares to $120 from $84, maintaining an Outperform rating, following positive SKYLINE Part A data for SPY001 and SPY002. The firm believes this data positions SPY120 for superior clinical remission rates i

Tone
Positive 81/100
Event
Analyst action
Published
13 Jul 2026 12:10
Source
Investing.com Australia
GuruFocus Direct company coverage

SYRE Maintained by Mizuho -- Price Target Raised to $120

Mizuho has maintained an "Outperform" rating for Spyre Therapeutics Inc (SYRE) and raised its price target to $120, up from $84. This reflects optimism about the company's potential in the biotechnology sector, particularly in treating inflammatory bowel disease and rheumatic dis

Tone
Positive 70/100
Event
Analyst action
Published
13 Jul 2026 12:10
Source
GuruFocus
marketscreener.com Direct company coverage

Mizuho Raises Price Target on Spyre Therapeutics to $120 From $84, Keeps Outperform Rating

Mizuho has increased its price target for Spyre Therapeutics to $120 from $84, while maintaining an "Outperform" rating on the stock. This adjustment comes after Spyre Therapeutics reported positive initial 12-week induction topline data from its Phase 2 SKYLINE trial for SPY002

Tone
Positive 72/100
Event
Analyst action
Published
13 Jul 2026 11:10
Source
marketscreener.com
Moomoo Direct company coverage

Spyre Therapeutics Insider Sold Shares Worth $1,315,346, According to a Recent SEC Filing

A recent SEC filing revealed that a Spyre Therapeutics insider sold shares totaling $1,315,346. Details about the insider and the specific transaction date were not provided in this summary. Such sales are often publicly disclosed to ensure transparency in market activities.

Tone
Negative 39/100
Event
Market update
Published
11 Jul 2026 23:10
Source
Moomoo
Simply Wall Street Direct company coverage

Spyre Therapeutics (SYRE) Faces Broad Russell Index Removal Is Benchmark Appeal Quietly Eroding?

Spyre Therapeutics (SYRE) was recently removed from several Russell indices, impacting its appeal to benchmark-driven investors and potentially altering its trading patterns and liquidity. The company, a pre-revenue biotech, relies on its pipeline of TL1A and gut-selective antibo

Tone
Negative 35/100
Event
Balance sheet
Published
10 Jul 2026 22:11
Source
Simply Wall Street
TradingView Direct company coverage

Price to sales forward of Spyre Therapeutics, Inc – LSX:A3D4LY

This page provides financial information for Spyre Therapeutics, Inc. (LSX:A3D4LY) on TradingView, specifically focusing on its price-to-sales forward metric. The content highlights that the market for this stock is currently closed with no trades.

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 17:40
Source
TradingView
TradingView Direct company coverage

Price to book forward of Spyre Therapeutics, Inc – LSX:A3D4LY

This page provides financial data for Spyre Therapeutics, Inc (LSX:A3D4LY), specifically focusing on its forward price-to-book ratio. The content indicates that the market was closed at the time of viewing, with no trades observed. It also details the various data providers and c

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 11:12
Source
TradingView
timothysykes.com Direct company coverage

Spyre Therapeutics Inc. (SYRE) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Spyre Therapeutics Inc. (SYRE) stock on NASDAQ. It includes current pricing information, a daily candlestick chart, and notes that there are no analyst ratings or earnings information currently available for the company. The page also

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 09:40
Source
timothysykes.com
StocksToTrade Direct company coverage

Spyre Therapeutics (SYRE) Draws Bullish Targets Amid Volatile Trading

Spyre Therapeutics (SYRE) is experiencing volatile trading despite positive clinical trial results for its SPY002 drug in ulcerative colitis, leading analysts to raise price targets. Insider stock sales, however, caused a temporary selloff. The company maintains a strong cash pos

Tone
Positive 64/100
Event
Earnings
Published
07 Jul 2026 20:12
Source
StocksToTrade
Quartr Direct company coverage

Spyre Therapeutics (SYRE) Study result Summary

Spyre Therapeutics announced positive results from Part A of its SKYLINE Phase 2 study for SPY001 in moderately to severely active ulcerative colitis, meeting primary and key secondary endpoints. SPY001, an optimized anti-alpha-4 beta-7 antibody, demonstrated significant efficacy

Tone
Positive 94/100
Event
Earnings
Published
06 Jul 2026 09:41
Source
Quartr
Quartr Direct company coverage

Spyre Therapeutics (SYRE) Leerink Global Healthcare Conference 2026 Summary

Spyre Therapeutics presented at the Leerink Global Healthcare Conference 2026, outlining its strategy to develop best-in-class biologics for autoimmune diseases, primarily focusing on IBD and rheumatology. The company is advancing combination therapies using optimized antibodies

Tone
Positive 73/100
Event
Market update
Published
06 Jul 2026 09:40
Source
Quartr
Sahm Direct company coverage

Will Spyre’s US$500 Million ATM and Russell Exit Change Spyre Therapeutics' (SYRE) Narrative

Spyre Therapeutics recently filed a US$500 million at-the-market equity offering and an omnibus shelf registration, while also being removed from several Russell Value indexes. This article explores how these developments, particularly the large equity program, will impact Spyre'

Tone
Negative 38/100
Event
Market update
Published
04 Jul 2026 08:40
Source
Sahm
Investing.com Direct company coverage

Spyre Therapeutics CEO Cameron Turtle sells $1.32m in shares

Spyre Therapeutics CEO Cameron Turtle sold 15,000 shares of the company's common stock for approximately $1.32 million on July 1, 2026, as part of a Rule 10b5-1 trading plan. These sales occurred after a significant 450% stock return over the past year, with the stock trading at

Tone
Negative 38/100
Event
Market update
Published
03 Jul 2026 07:40
Source
Investing.com
Investing.com Direct company coverage

Spyre Therapeutics (NASDAQ:SYRE) CFO Scott Burrows sells $658k in shares

Spyre Therapeutics CFO Scott Burrows sold 7,500 shares of the company's common stock for over $658,000 on July 1, 2026, following the exercise of stock options. The sales were executed under a Rule 10b5-1 trading plan and involved shares sold at weighted average prices between $8

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 03:12
Source
Investing.com
Stock Titan Direct company coverage

[Form 4] Spyre Therapeutics, Inc. Insider Trading Activity

Sheldon Sloan, Chief Medical Officer at Spyre Therapeutics, Inc., exercised options for 8,334 shares of common stock at $27.46 per share and subsequently sold them on July 1, 2026, at weighted average prices of $87.52 and $88.34. These transactions were executed under a Rule 10b5

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 02:12
Source
Stock Titan
Stock Titan Direct company coverage

Spyre Therapeutics (SYRE) CFO exercises options, sells 7,500 shares under 10b5-1 plan

Spyre Therapeutics' CFO, Scott L. Burrows, exercised stock options for 7,500 shares at $14.50 and subsequently sold these shares in the open market at weighted average prices of $87.55 and $88.37. These transactions were executed on July 1, 2026, under a pre-arranged Rule 10b5-1

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 02:12
Source
Stock Titan
The Globe and Mail Direct company coverage

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics, Inc. announced the grant of inducement awards to six non-executive employees, including stock options to purchase 58,843 shares and 2,134 restricted stock units (RSUs). These awards were approved by the independent Compensation Committee of the Board of Direct

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:12
Source
The Globe and Mail
Investing.com Canada Direct company coverage

Form 144 SPYRE THERAPEUTICS INC For: 1 July By Investing.com

This article consists solely of a short announcement that SPYRE THERAPEUTICS INC filed a Form 144 for July 1st. It provides no further details regarding the content of the filing or its implications. The content is primarily a header and repeated small text mentions of the filing

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 22:09
Source
Investing.com Canada
Stock Titan Direct company coverage

SYRE (NASDAQ) Form 144: Insider sales and 45,000-share notice

Spyre Therapeutics (SYRE) submitted a Form 144 notice for the proposed sale of 45,000 shares of Common Stock, linked to options exercised in June 2023. The filing also detailed two Rule 10b5-1 transactions by Cameron W. Turtle in May and June 2026, each for 15,000 shares, totalin

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 21:09
Source
Stock Titan
Seeking Alpha Direct company coverage

Spyre Therapeutics: Deep And Diverse Immunology Pipeline Awaiting Data (NASDAQ:SYRE)

Spyre Therapeutics is a clinical-stage immunology company developing long-acting antibody therapies for inflammatory bowel disease (IBD) and rheumatology. The company has a well-funded balance sheet, allowing it to advance its Phase 2 assets, SPY001 and SPY002, which have shown e

Tone
Positive 62/100
Event
Market update
Published
30 Jun 2026 12:11
Source
Seeking Alpha
TradingView Direct company coverage

Spyre Therapeutics Stock Outlook Hinges on 2026 Study Catalysts

Spyre Therapeutics is a clinical-stage biotech company focusing on inflammatory bowel disease (IBD) with a diverse pipeline of long-acting antibodies. The company's stock outlook for 2026 is heavily dependent on the clinical proof-of-concept data from its six upcoming Phase II st

Tone
Neutral 50/100
Event
Guidance
Published
29 Jun 2026 15:41
Source
TradingView
TradingView Direct company coverage

Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today

Spyre Therapeutics (SYRE) presents a dilemma for investors: while its pipeline is advancing and it boasts a large cash balance, the stock has already seen significant gains without commercial product revenue. Its high valuation reflects future clinical success that is yet to be p

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 15:41
Source
TradingView
Moomoo Direct company coverage

Spyre Therapeutics Insider Sold Shares Worth $1,307,000, According to a Recent SEC Filing

A recent SEC filing revealed that an insider at Spyre Therapeutics sold shares valued at $1,307,000. This transaction could be a routine part of an insider's financial planning or may indicate a change in their outlook on the company's stock. Investors often monitor insider trans

Tone
Negative 20/100
Event
Guidance
Published
29 Jun 2026 07:10
Source
Moomoo